Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Cancer Immunology, Immunotherapy

Volumn 57, Issue 3, 2008, Pages 303-315

  Janetzki, Sylvia ^a,b   Panageas, Katherine S ^c   Ben Porat, Leah ^c   Boyer, Jean ^d   Britten, Cedrik M ^e   Clay, Timothy M ^f   Kalos, Michael ^g   Maecker, Holden T ^h   Romero, Pedro ⁱ   Yuan, Jianda ^c   Martin Kast, W ^j   Hoos, Axel ^k  

^a ZellNet Consulting Inc ^*  (United States)

^b ZellNet Consulting Inc   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f DUKE CANCER INSTITUTE   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h BD BIOSCIENCES   (United States)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Elispot; Harmonization; Immune monitoring; Proficiency panel; Validation

Indexed keywords

CANCER VACCINE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; ENZYME LINKED IMMUNOSPOT ASSAY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; INCUBATION TIME; PERFORMANCE; PLATING MEDIUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

CANCER VACCINES; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEALTH SURVEYS; HUMANS; INTERNATIONAL COOPERATION; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; PEPTIDES; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOCIETIES;

EID: 37349020262     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0380-6     Document Type: Article

References (39)

1. Asai T, Storkus WJ, Whiteside TL (2000) Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol 7:145-154
2. Britten CM, Gouttefangeas C, Schoenmaekers-Welters MJP, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T and Van der Burg SH (2007) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (in press). doi: 10.1007/s00262-007-0379-z
3. Cox J (2005) Conducting a multi-site Elispot proficiency panel. http://www.zellnet.com/february2005/
4. Cox JH, Ferrari G, Bailer RT, Koup RA (2004) Automating procedures for processing, cryopreservation, storage and manipulation of human peripheral mononuclear cells. J Assoc Lab Automat 9:16-23
5. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'Souza MP, Elispot Collaborative Study Group (2005) Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21:68-81
6. Cox JH, Ferrari G, Janetzki S (2006) Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods 38:274-282
7. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260:157-172
8. Dubey S, Clair J, Fu T-M, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW (2007) Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-lined immunospot assay. J Acquir Immune Defic Syndr 45:20-27
9. FDA Guideline for Industry. Text on validation of Analytical Procedures. http://www.fda.gov/cder/guidance/ichq2a.pdf
10. Findlay JWA; Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, Khan MN, Bowsher RR (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21:1249-1273
11. Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay T, (2005) Enumerating antigen-specific T-cell responses in peripheral blood. J Immunother 28:63-72
12. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G, Cancer Vaccine Clinical Trial Working Group (2007) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1-15
13. International Conference on Harmonisation (ICH); Guidance for Industry: Q2B Validation of Analytical Procedures: Methodology (1997) http://www.fda.gov/ cber/gdlns/ichq2bmeth.pdf
14. Janetzki S (2004) Automation of the Elispot technique: past, present and future. J Assoc Lab Automat 9:10-15
15. Janetzki S, Schaed S, Blachere NE, Ben-Porat L, Houghton AN, Panageas KS (2004) Evaluation of Elispot assays: influence of method and operator on variability of results. J Immunol Methods 291:175-183
16. Janetzki S, Cox JH, Oden N, Ferrari G (2006) Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 302:51-86
17. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97-138
18. Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, Fernandez VR, Long R, Guan L, Gaunt C, Collins K, Sykes KJ, Mehrotra DV, Chirmule N, Shiver JW, Casimiro DR (2007) Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses 23:86-92
19. Lathey J (2003) Preliminary steps toward validating a clinical bioassay. Biopharm Int 16:42-50
20. Lathey JL, Martinez K, Gregory S, D'Souza P, Lopaczynski W (2005) Characterization of assay variability in real-time and batch assays of sequential samples from the same donors. FOCIS 5th Annual Meeting, Poster, Abstract# Su2.96
21. Lem L (2003) Cell counting and viability assessments in the process development of cellular therapeutics. BioProcessing J July/August:57-60
22. Maecker T (2005) The role of immune monitoring in evaluating cancer immunotherapy. In: Disis ML (ed) Cancer drug discovery and development: immunotherapy of cancer. Humana Press Inc., NJ, pp 59-72
23. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LJ (2001) Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 255:27-40
24. Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK (2001) Surrogate markers of response to cancer immunotherapy. Expert Opin Biol Ther 1:153-158
25. Mwau M, McMichael AJ, Hanke T (2002) Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18:611-618
26. Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U (2004) Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther 4:1677-1684
27. NCCLS (2001) Evaluation of matrix effects, approved guidelines. NCCLS document EP14-A
28. NCCLS (2004) Performance of single cell immune response assays; approved guidelines. NCCLS document I/LA26-A
29. NIAID Division of AIDS (2003) Validating an immunological assay toward licensure of a vaccine. http://www.niaid.nih.gov/hivvaccines/validation.htm
30. Pifat D (2006) Assay validation. http://www.fda.gov/cber/summaries/ 120600bio10.ppt
31. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ (2003) Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 187:226-242
32. Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, Sinet M, Tartour E, Aboulker J-P, Autran B, Venet A, The ANRS Elispot Standardization Group (2006) Evaluation of the interlaboratory concordance in quantification of HIV-specific T cells with a gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol 13:684-697
33. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini J-C, Woelfel T, Eggermont AMM, Keilholz U (2000) Quantitation of antigen-reactive T cells in peripheral blood by IFNg-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 244:81-89
34. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ (2001) Development and validation of a gamma Interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 8:871-879
35. Smith JG, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM, Antonello J, Caulfield MJ (2007) Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol 14:527-537
36. Tuomela M, Stanescu I, Krohn K (2005) Validation overview of bio-analytical methods. Gene Ther 12(Suppl 1):131-138
37. United States Pharmacopeia-USP (1999) Validation of compendial methods. Suppl 10, pp 5059-5062
38. Walker EB, Disis ML (2003) Monitoring immune responses in cancer patients receiving tumor vaccines. Int Rev Immunol 22:283-319
39. Whiteside TL (2000) Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest 29:149-162